Business Description
Zhejiang Medicine Co Ltd
ISIN : CNE0000010J2
Share Class Description:
SHSE:600216: Class ATotal Employee Number:
5,417Compare
Compare
Traded in other countries / regions
600216.China Index Membership
SSE Composite IndexCSI 500 Index IPO Date
1999-10-21Description
Zhejiang Medicine Co Ltd is engaged in the Nutritional supplements, pharmaceutical manufacturing products, and pharmaceutical commerce.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.38 | |||||
Equity-to-Asset | 0.79 | |||||
Debt-to-Equity | 0.09 | |||||
Debt-to-EBITDA | 1.16 | |||||
Interest Coverage | 40.4 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 4.42 | |||||
Beneish M-Score | -2.58 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 3.2 | |||||
3-Year EBITDA Growth Rate | 13.8 | |||||
3-Year EPS without NRI Growth Rate | 17.2 | |||||
3-Year Book Growth Rate | 5.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 13.93 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 3.41 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 51.18 | |||||
9-Day RSI | 50.98 | |||||
14-Day RSI | 48.03 | |||||
3-1 Month Momentum % | -25.66 | |||||
6-1 Month Momentum % | -12.7 | |||||
12-1 Month Momentum % | -20.35 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.39 | |||||
Quick Ratio | 2.54 | |||||
Cash Ratio | 1.53 | |||||
Days Inventory | 121.34 | |||||
Days Sales Outstanding | 64.86 | |||||
Days Payable | 65.19 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 3.06 | |||||
Dividend Payout Ratio | 0.41 | |||||
3-Year Dividend Growth Rate | 3.9 | |||||
Forward Dividend Yield % | 2.31 | |||||
5-Year Yield-on-Cost % | 1.09 | |||||
3-Year Average Share Buyback Ratio | 0.1 | |||||
Shareholder Yield % | 1.77 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 32.53 | |||||
Operating Margin % | 10.95 | |||||
Net Margin % | 8.52 | |||||
EBITDA Margin % | 9.4 | |||||
FCF Margin % | 13.69 | |||||
OCF Margin % | 19.07 | |||||
ROE % | 6.77 | |||||
ROA % | 5.32 | |||||
ROIC % | 8.13 | |||||
3-Year ROIIC % | 1542.94 | |||||
ROC (Joel Greenblatt) % | 10.46 | |||||
ROCE % | 7.05 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 15.38 | |||||
Forward PE Ratio | 10.81 | |||||
PE Ratio without NRI | 13.35 | |||||
Shiller PE Ratio | 17.14 | |||||
Price-to-Owner-Earnings | 923.11 | |||||
PEG Ratio | 3.34 | |||||
PS Ratio | 1.3 | |||||
PB Ratio | 1.03 | |||||
Price-to-Tangible-Book | 1.09 | |||||
Price-to-Free-Cash-Flow | 9.6 | |||||
Price-to-Operating-Cash-Flow | 6.87 | |||||
EV-to-EBIT | 12.2 | |||||
EV-to-EBITDA | 12.2 | |||||
EV-to-Revenue | 1.15 | |||||
EV-to-FCF | 8.37 | |||||
Price-to-GF-Value | 0.87 | |||||
Price-to-Projected-FCF | 0.93 | |||||
Price-to-DCF (Earnings Based) | 1.16 | |||||
Price-to-DCF (FCF Based) | 0.83 | |||||
Price-to-Median-PS-Value | 0.78 | |||||
Price-to-Graham-Number | 0.8 | |||||
| Price-to-Net-Current-Asset-Value | 2.74 | |||||
| Price-to-Net-Cash | 38.71 | |||||
Earnings Yield (Greenblatt) % | 8.2 | |||||
FCF Yield % | 10.46 | |||||
Forward Rate of Return (Yacktman) % | 5.28 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Zhejiang Medicine Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 8,816.078 | ||
| EPS (TTM) (Â¥) | 0.78 | ||
| Beta | 0.7732 | ||
| 3-Year Sharpe Ratio | 0.06 | ||
| 3-Year Sortino Ratio | 0.09 | ||
| Volatility % | 27.3 | ||
| 14-Day RSI | 48.03 | ||
| 14-Day ATR (Â¥) | 0.452187 | ||
| 20-Day SMA (Â¥) | 11.8695 | ||
| 12-1 Month Momentum % | -20.35 | ||
| 52-Week Range (Â¥) | 10.94 - 18.58 | ||
| Shares Outstanding (Mil) | 961.64 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Zhejiang Medicine Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Zhejiang Medicine Co Ltd Stock Events
| Event | Date | Price (Â¥) | ||
|---|---|---|---|---|
| CNY 0.280000 Cash Dividend | 2026-07-09 | In 1 day | ||
| CNY 0.370000 Cash Dividend | 2025-07-21 | 15.45 (-0.52%) | ||
| CNY 0.150000 Cash Dividend | 2024-07-10 | 11.14 (+2.20%) | ||
| 1.8:1 Stock Split | 2013-10-09 | 12.38 (-0.71%) | ||
| 1.33:1 Stock Split | 2006-03-07 | 2.51 (+0.00%) | ||
| 1.5:1 Stock Split | 2001-05-25 | 5.06 (-2.15%) | ||
| 1.3:1 Stock Split | 2000-10-09 | 4.30 (-0.50%) |
Show
Entries
Zhejiang Medicine Co Ltd Frequently Asked Questions
What is Zhejiang Medicine Co Ltd(SHSE:600216)'s stock price today?
The current price of SHSE:600216 is ¥12.00. The 52 week high of SHSE:600216 is ¥18.58 and 52 week low is ¥10.94.
When is next earnings date of Zhejiang Medicine Co Ltd(SHSE:600216)?
The next earnings date of Zhejiang Medicine Co Ltd(SHSE:600216) is .
Does Zhejiang Medicine Co Ltd(SHSE:600216) pay dividends? If so, how much?
The Dividend Yield %  of Zhejiang Medicine Co Ltd(SHSE:600216) is 3.06% (As of Today), Highest Dividend Payout Ratio of Zhejiang Medicine Co Ltd(SHSE:600216) was 1.64. The lowest was 0.1. And the median was 0.52. The  Forward Dividend Yield % of Zhejiang Medicine Co Ltd(SHSE:600216) is 2.31%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Ambrx and NovoCodex form Second Collaboration to Develop and Commercialize Ambrx's Antibody Drug Conjugates | 2019-10-23 |
Articles on Zhejiang Medicine Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers